Moderna, Inc. vs Twist Bioscience Corp — how do they compare? Moderna, Inc. trades at $59.72 (market cap $23.60B), while Twist Bioscience Corp trades at $88.31 (market cap $5.45B). The key difference: Moderna, Inc. is far larger — about 4.3× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Moderna, Inc. nearer its low. Which is the better fit depends on your goals.
| MRNA | TWST | |
|---|---|---|
Market Cap | $23.60B | $5.45B |
Sector | Health | Health |
52-Week High | $81.80 | $102.88 |
52-Week Low | $22.36 | $24.16 |
Enterprise Value | $19.70B | $5.37B |
Trailing returns across standard periods
Latest headlines on both assets
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →